T3 Pharmaceuticals is a pre-clinical biopharmaceutical company focused on developing next-generation bacterial cancer therapies. The company leverages live bacteria to deliver highly specific and efficient treatments aimed at improving the lives of cancer patients. Founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz, and Helmut Kessmann, T3 Pharmaceuticals operates in the oncology market, targeting unmet needs in cancer treatment. The business model revolves around research and development, with a focus on creating innovative therapies that can be commercialized through partnerships or direct sales. Revenue is generated through licensing agreements, research grants, and potential future sales of approved therapies. The company serves healthcare providers, research institutions, and ultimately cancer patients who require novel treatment options.

Keywords: bacterial cancer therapy, live bacteria, oncology, cancer treatment, biopharmaceutical, innovative therapies, pre-clinical, research and development, specific treatments, efficient treatments.